Boston Scientific continues buying binge with Meadox deal.
This article was originally published in The Gray Sheet
Executive Summary
BOSTON SCIENTIFIC GRAFTING ON MEADOX MEDICALS IN $425 MIL. STOCK SWAP merger. Continuing its buying binge, emerging cardiovascular conglomerate Boston Scientific announced on Sept. 29 that it has entered into a definitive merger agreement with privately held Meadox, which manufactures vascular replacement products.